BlackRock
VERV

BlackRock’s Verve Therapeutics VERV Stock Holding History

BlackRock’s Portfolio VERV Stock Details VERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-7,356,721
Closed -$82.6M – 5610
2025
Q2 		$82.6M Sell
7,356,721
-521,515
-7% -$2.97M ﹤0.01% 2169
2025
Q1 		$36M Buy
7,878,236
+352,766
+5% +$2.36M ﹤0.01% 2565
2024
Q4 		$42.4M Buy
7,525,470
+249,123
+3% +$1.41M ﹤0.01% 2556
2024
Q3 		$35.2M Buy
7,276,347
+656,343
+10% +$3.81M ﹤0.01% 2687
2024
Q2 		$32.3M Buy
6,620,004
+1,246,827
+23% +$7.84M ﹤0.01% 2700
2024
Q1 		$71.4M Buy
5,373,177
+937,696
+21% +$12.4M ﹤0.01% 2251
2023
Q4 		$61.8M Buy
4,435,481
+437,082
+11% +$5.42M ﹤0.01% 2350
2023
Q3 		$53M Buy
3,998,399
+151,696
+4% +$2.44M ﹤0.01% 2369
2023
Q2 		$72.1M Buy
3,846,703
+300,218
+8% +$5M ﹤0.01% 2267
2023
Q1 		$51.1M Sell
3,546,485
-47,589
-1% -$932K ﹤0.01% 2426
2022
Q4 		$69.5M Buy
3,594,074
+217,864
+6% +$5.77M ﹤0.01% 2243
2022
Q3 		$116M Buy
3,376,210
+792,139
+31% +$25.3M ﹤0.01% 1865
2022
Q2 		$39.5M Buy
2,584,071
+425,509
+20% +$6.59M ﹤0.01% 2644
2022
Q1 		$49.3M Buy
2,158,562
+915,090
+74% +$26.2M ﹤0.01% 2599
2021
Q4 		$45.8M Buy
1,243,472
+299,015
+32% +$12.6M ﹤0.01% 2709
2021
Q3 		$44.4M Buy
944,457
+414,533
+78% +$24.4M ﹤0.01% 2743
2021
Q2 		$31.9M Buy
+529,924
New +$22M ﹤0.01% 3008

Other funds holding VERV

GCM
Greenland Capital Management New York $812M AUM 45.54% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return
BIG
Brooklyn Investment Group Brooklyn, New York $3.2B AUM 26.32% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

BlackRock's VERV Position: Q3 2025 in Review

BlackRock sold out of Verve Therapeutics (VERV) in Q3 2025, closing a stake of 7,356,721 shares — an estimated $82.6M sold.

BlackRock first reported a position in VERV in Q2 2021 and held it in 17 quarters. The position peaked at $116M in Q3 2022. 6 funds tracked by Wall St. Rank hold VERV as of Q3 2025.

  • BlackRock reported no remaining Verve Therapeutics position as of Q3 2025 after selling out during the quarter.
  • BlackRock sold 7,356,721 Verve Therapeutics shares in Q3 2025, an estimated $82.6M.
  • BlackRock first reported a position in Verve Therapeutics in Q2 2021 and held it in 17 quarters.
  • BlackRock's Verve Therapeutics position peaked at $116M in Q3 2022.
  • 6 funds tracked by Wall St. Rank held Verve Therapeutics as of Q3 2025.

Based on BlackRock's 13F filing for Q3 2025, filed 12 Nov 2025.